TNF and Splenomegaly: MTX was then discontinued, and she was started back on steroids and TNF inhibitor, adalimumab, with the goal to taper steroids once ANC becomes stable on the TNF inhibitor, treating for possible FA in the setting of autoimmune neutropenia, seropositive RA, and moderate splenomegaly/hepatomegaly on US abdomen (completed in the summer of 2022).